24 May 2013
Keywords: xanthus, xanafide, sees, good, safety, data, cancer
Article | 30 May 2005
US cancer specialist Xanthus Life Sciences has revealed positive data from a Phase I study of Xanafide (amonafide) in combination ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
30 May 2005
23 May 2005
23 May 2013
© 2013 thepharmaletter.com